Stem Cell Microglia Transplant Leukodystrophy Treatment
Summary
USPTO published patent application US20260108560A1 titled 'Transplanting Stem Cell-Derived Microglia to Treat Leukodystrophies' on April 23, 2026. The application covers myeloid cells, microglial progenitor cells, and microglia-like cells in which mutant genes have been repaired or replaced, and methods of using such cells to treat disease. Seven inventors are named including Mathew Blurton-Jones, Hayk Davtyan, Jean Paul Chadarevian, Robert Spitale, Sunil Gandhi, Jonathan Hasselmann, and Whitney England.
“The resulting cells were differentiated into microglial progenitors and then transplanted into the brain of xenotransplantation-compatible CSF1R-AFIRE/AFIRE mice, thereby preventing or reversing phenotypes associated with leukodystrophy, including thalamic microbleeds, calcification, astrogliosis, axonal spheroids, synaptic loss, and accumulation of Tau phosphorylated at threonine residue 217.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108560A1 for stem cell-derived microglia transplant methods to treat leukodystrophies. The application discloses correction of CSF1R mutations in human induced pluripotent stem cells, differentiation into microglial progenitors, and transplantation into CSF1R-AFIRE/AFIRE mice to prevent or reverse leukodystrophy phenotypes.
This publication represents an early-stage intellectual property filing with no immediate compliance implications for pharmaceutical or medical device manufacturers. Researchers and biotech companies working on microglia-based therapies or leukodystrophy treatments should monitor this application's prosecution for potential freedom-to-operate considerations once granted.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
TRANSPLANTING STEM CELL-DERIVED MICROGLIA TO TREAT LEUKODYSTROPHIES
Application US20260108560A1 Kind: A1 Apr 23, 2026
Inventors
Mathew Blurton-Jones, Hayk Davtyan, Jean Paul Chadarevian, Robert Spitale, Sunil Gandhi, Jonathan Hasselmann, Whitney England
Abstract
The present disclosure provides myeloid cells, microglial progenitor cells, and microglia-like cells in which a mutant gene has been repaired or replaced, and methods of using such cells to treat disease. Mutations in CSF1R were corrected in human induced pluripotent stem cells. The resulting cells were differentiated into microglial progenitors and then transplanted into the brain of xenotransplantation-compatible CSF1R-AFIRE/AFIRE mice, thereby preventing or reversing phenotypes associated with leukodystrophy, including thalamic microbleeds, calcification, astrogliosis, axonal spheroids, synaptic loss, and accumulation of Tau phosphorylated at threonine residue 217.
CPC Classifications
A61K 35/30 A61P 25/28 C07K 14/7153 C12N 5/0622 C12N 5/10 C12N 15/85 C12N 2506/45 C12N 2510/00
Filing Date
2023-07-13
Application No.
18993901
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.